Somatic mutations of FGFR2 and FGFR3 were reported in 12% and 30% of endometrial and urothelial cell carcinomas, respectively.[35, 36] Inhibitor–sensitive 5 mutation loci for FGFR2 and 6 mutation loci for FGFR3 were noticed in 3% of lung SqCC samples.[37]Here, we show no FGFR2 and FGFR3 mutations in our 388 ESCC patients. This evidence concerns the gene FGFR3 and esophageal squamous cell carcinoma.